Skip to Content

Eltrombopag Disease Interactions

There are 4 disease interactions with eltrombopag:


Eltrombopag (Includes eltrombopag) ↔ hepatitis C

Severe Potential Hazard, Moderate plausibility. Applies to: Infectious Hepatitis

Eltrombopag has shown to increase the risk of hepatic decompensation in patients with chronic hepatitis C in treatment with interferon and ribavirin. Clinical trials reported that ascites and encephalopathy occurred more frequently on these patients than in the placebo arm. Patients with chronic hepatitis and receiving antiviral treatment should be closely monitored. The manufacturers also recommend to discontinue eltrombopag if the antiviral therapy is discontinued.


Eltrombopag (Includes eltrombopag) ↔ hepatotoxicity / hepatic dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Eltrombopag can cause liver enzyme elevations. Monitor ALT, AST and bilirubin prior to treatment initiation, and every 2 weeks during dose adjustment phase and then monthly. If abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized. Treatment should be discontinued if ALT levels increase to greater than or equal to 3 x ULN in patients with normal liver function, or greater or equal to 3 x baseline in patients with pretreatment transaminase elevations that are progressively increasing, persist for 4 weeks or more, also have an increase in bilirubin, or also have clinical symptoms of liver injury or hepatic decompensation.

Hepatic impairment influences the exposure to eltrombopag. The initial dose should be reduced in patients with chronic ITP or severe aplastic anemia who have hepatic impairment. No dose adjustment is required on patients with chronic hepatitis C and hepatic impairment.


Eltrombopag (Includes eltrombopag) ↔ cataracts

Moderate Potential Hazard, Moderate plausibility. Applies to: Cataracts

In clinical trials, eltrombopag developed or worsened cataracts in 7% of the patients receiving treatment. A baseline ocular examination prior to administration of eltrombopag is recommended, and regular monitoring for signs and symptoms of cataracts should be performed regularly during treatment.


Eltrombopag (Includes eltrombopag) ↔ thrombotic / thromboembolic complications

Moderate Potential Hazard, Moderate plausibility. Applies to: Thrombotic/Thromboembolic Disorder

Thromboembolic complications may result from increases in platelet counts with eltrombopag. Consider the potential for increased risk of thromboembolism when administering eltrombopag to patients with known risk factors for thromboembolism.

Eltrombopag drug interactions

There are 207 drug interactions with eltrombopag

Eltrombopag alcohol/food interactions

There are 2 alcohol/food interactions with eltrombopag

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.